Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: A 6-month, masked, multicenter trial

Ophthalmology

Volumn 109, Issue 5, 2002, Pages 998-1008

  Fellman, Ronald L ^a,d   Sullivan, E Kenneth ^b   Ratliff, Marla ^b   Silver, Lewis H ^a   Whitson, Jess T ^c   Turner, F Darell ^b   Weiner, Alan L ^b   Davis, Alberta A ^b  

^a Glaucoma Associates of Texas   (United States)

^b ALCON RESEARCH LTD   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIMOLOL; TIMOLOL MALEATE; TRAVOPROST;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; ASTHENIA; BRADYCARDIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOREIGN BODY; GLAUCOMA; HEART ARRHYTHMIA; HUMAN; HYPEREMIA; HYPOTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PULSE PRESSURE; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; VERTIGO;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLOPROSTENOL; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; GLAUCOMA, OPEN-ANGLE; HEART RATE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; SAFETY; TIMOLOL; TREATMENT OUTCOME;

EID: 0036236701     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(02)01010-2     Document Type: Article

References (24)

1. The advanced glaucoma intervention study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration
2. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma
3. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals: A randomized double-masked, long-term clinical trial
4. Does glaucomatous visual field loss continue despite surgically subnormal IOP?
5. Cardiovascular effects of topical beta-blockers during exercise
6. Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers
7. Effects of β-adrenoceptors blocking eye drops in patients with chronic bronchitis
8. Changes in lung function following administration of eyedrops containing timolol, metipranolol, pindolol and pilocarpine in healthy probands and patients with mild bronchial asthma
9. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis
10. Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension
11. Anterior uveitis associated with latanoprost
12. Latanoprost-associated cystoid macular edema
13. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension
14. 3H] 9β -(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor
15. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphor-imaging technology
16. Preclinical efficacy of travoprost, a potent and selective fp prostaglandin agonist
17. 2α-isopropyl ester
18. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma
19. A six-month, randomized, double-masked study comparing latanoprost to timolol in open-angle glaucoma and ocular hypertension
20. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning
21. Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: A 3-month clinical trial